25-28. (canceled)

29. The method of claim **1**, wherein said ASC originate from placenta tissue and are at least predominantly maternal cells.

30-31. (canceled)

32. The method of claim **1**, wherein said ASC originate from placenta tissue and are at least predominantly fetal cells.

33. (canceled)

34. The method of claim **1**, wherein said ASC express a marker selected from the group consisting of CD73, CD90, CD29 and CD105.

35-37. (canceled)

38. The method of claim **1**, wherein said cancer is selected from osteosarcoma, prostate carcinoma, urothelial bladder carcinoma, renal cell adenocarcinoma, gastric adenocarcinoma, pancreatic adenocarcinoma, breast ductal carcinoma, hepatocellular carcinoma, squamous cell carcinoma, thyroid anaplastic carcinoma, lung anaplastic carcinoma, melanoma, colorectal adenocarcinoma, glioblastoma, prostate carcinoma, ovarian clear cell carcinoma, uterine sarcoma, lung adenocarcinoma, bronchoalveolar carcinoma, large cell lung carcinoma, rhabdomyosarcoma, neuroblastoma, astrocytoma, and rectum adenocarcinoma.

39. (canceled)

40. The method of claim **1**, wherein said cancer is a breast carcinoma.

41. (canceled)

42. The method of claim **40**, wherein said breast carcinoma is triple negative.

43. (canceled)

44. The method of claim **1**, wherein said ASC are administered systemically.

45. The method of claim **1**, wherein said ASC are administered intramuscularly, intravenously (IV), subcutaneously (SC), by an intraosseous route, or intraperitoneally (IP).

46. The method of claim **1**, wherein said ASC are administered intratumorally.

47. A method of inhibiting a metastasis of a tumor in a subject at risk thereof, the method comprising administering to the subject adherent stromal cells (ASC), thereby inhibiting a metastasis of a tumor in the subject.

* * * * *